SCHEMBL7225567

SCHEMBL7225567

CC(=O)O[C@H]1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2CCC4C)CC1(C)C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.69
KDM4E B2RXH2 9/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CYP1A2 P05177 1/20 0.48
ALDH1A1 P00352 5/20 0.46
HPGD P15428 5/20 0.46
HSD17B10 Q99714 3/20 0.46
ALB P02768 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
POLB P06746 3/20 0.46
AADAT Q8N5Z0 2/20 0.46
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
TUBA1B P68363 1/20 0.46
TUBA4A P68366 1/20 0.46
TUBB4B P68371 1/20 0.46
TUBB3 Q13509 1/20 0.46
TUBB2A Q13885 1/20 0.46
TUBB8 Q3ZCM7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7226968 0.92 LMNA (0.65) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7226259 0.91 LMNA (0.66) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7225205 0.90 LMNA (0.79) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL3971386 0.87 LMNA (0.78) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL10996219 0.87 LMNA (0.78) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7226579 0.84 LMNA (0.70) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7225726 0.84 LMNA (0.62) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7763545 0.83 LMNA (0.74) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7224626 0.83 LMNA (0.74) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL10994613 0.83 LMNA (0.87) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608078-B2 Gramnegative bacteria WOCKHARDT LIMITED (IN) 2003-08-19 US claimed
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment WOCKHARDT RESEARCH CENTER 2002-11-07 US claimed
US-6608078-B2 Gramnegative bacteria WOCKHARDT LIMITED (IN) 2003-08-19 US disclosed
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment WOCKHARDT RESEARCH CENTER 2002-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment ALPI, POLR1C, POLI LMNA 1788/4885KDM4E 2308/4885SMN1; SMN2 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.